

Medication: Clopidogrel (Plavix)	PDN: 6984.05	Last Updated: August 21 2025	PMD: Andrew Travers*	PDC: Teena Robinson*	Page 1 of 2
--	---------------------	--	--------------------------------	--------------------------------	-------------

CLOPIDOGREL (Plavix)

1.0 Classification

- Platelet aggregation inhibitor/antiplatelet (clopidogrel is not an anticoagulant).

2.0 Mechanism of Action

- Irreversible blockade of adenosine diphosphate (ADP) receptor on platelet cell membranes, inhibiting platelet aggregation.

3.0 Indications

- For the treatment of ST segment elevation myocardial infarction (STEMI) of less than twelve (12) hours duration and more than twenty (20) minutes duration when TNK is being administered.

4.0 Contraindications

- Hypersensitivity
- Active bleeding
- Severe liver impairment or jaundice

5.0 Precautions

- None

6.0 Route

- May be given PO

7.0 Dosage

- **STEMI Receiving Pre-hospital Fibrinolysis:**
 - 300 mg for patients less than 75 years of age
 - 75 mg for patients 75 years of age and older

8.0 Supplied

- 75 mg and 300 mg tablets

9.0 May Be Given By

- PCP/ACP/CCP

10.0 Adverse Effects

- Chest Pain
- Increased risk of bleeding
- Bruising
- Itching/swelling/rash
- Nosebleed
- Generalized pain
- Influenza-like symptoms

11.0 Special Notes

- Standard ischemic chest pain management (ASA, nitroglycerin and opioids for severe pain)

- unresponsive to nitrates) should be continued as well.
- There is an increased risk of bleeding when clopidogrel is administered in conjunction with NSAIDs.
 - Pregnancy category C [if the patient will benefit from a Category C drug, it is generally used]

12.0 References

- Chest Pain Clinical Practice Guideline
- EHS STEMI Reperfusion Worksheet
- Compendium of Pharmaceuticals and Specialties (CPS)

*Electronically Signed

Copyright © Emergency Health Services